Ishita Drugs & Industries has announced a board meeting, approving the financial results for the quarter.

The Board also approved the re-appointment of Mrs. Abha Agrawal as a Non-Executive Non-Independent Director, pending shareholder approval, and accepted revised remuneration for the CFO.

A key operational update includes ongoing manufacturing facility upgrades, with 4.35 Cr spent and 5.65 Cr in contracts for equipment and utilities, as the company explores funding options.